West Pharmaceutical Services, Inc. (WST)

NYSE · Health Care · market cap 22.81B

Share price

$407.96

At the last nightly close

Intrinsic value

$147.96

Range $119.32 – $161.69 before any credit for growth. The figure above is $119.32 × 1.24, the credit the franchise record earns.

Margin of safety

-63.7%

($147.96 − $407.96) ÷ $407.96

EV / EBIT

121.5

On the median operating profit of 15 fiscal years through 2025.

How these numbers are computed

The valuations are calculated in Python from filed accounts, not written by a language model. Three methods run side by side: earnings power value, which capitalises a normalised operating profit; a free-cash-flow model; and the Graham Number as an asset-side cross-check. The conservative figure above starts from the lower of the first two; the Graham Number never enters it.

The frame gives no credit for growth unless the company has earned it: only a return on invested capital that has beaten the cost of capital year after year earns a growth credit, and that credit is capped. A company that compounds will therefore usually read as expensive against it — that is deliberate. It is a price-discipline floor, not a price target, and it is not a view on what the shares will do.

The EV/EBIT ranking uses the median operating profit of up to fifteen fiscal years — a full cycle — where the free screeners use the last twelve months. When the data cannot support a method, the figure reads n/a rather than a number: a free-cash-flow valuation on a bank, a PEG on erratic earnings, a multiple on a company with no operating profit to speak of.

Fundamentals from SEC EDGAR. Prices, market data and technicals from yfinance. Valuation computed 2026-11-03.

Key metrics

Price / earnings52.2

Price / book9.6

EV / EBITDA29.7

FCF / EV+0.6%

Return on equity+21.2%

Return on assets+11.9%

Debt / equity0.11

Gross margin+37.6%

Market position

52-week high$416.67

52-week low$230.63

From 52-week high-2.1%

RSI (14)69.4

200-day moving average$331.29

Annual financials

Period	Revenue	Operating income	Net income	EPS	Free cash flow
2025-FY	3.07B	636.1M	493.7M	6.83	468.9M
2024-FY	2.89B	590.9M	492.7M	6.75	276.4M
2023-FY	2.95B	707.4M	593.4M	7.98	414.5M
2022-FY	2.89B	760.8M	585.9M	7.87	439.4M
2021-FY	2.83B	752.3M	661.8M	8.67	330.6M

Filed figures from SEC EDGAR, in the reporting currency.

Next earnings

Q1 2027 expectedFebruary 18, 2027

Consensus EPS estimate2.28

Recent news

Headlines link to their source. Sperio does not republish article text.

The figures above are the arithmetic. To see what a board of eight AI agents makes of them — macro, sector, filings, news and a devil's advocate whose only job is to attack the thesis — run the full analysis on WST.

Run the board on WST

10 free analyses · no signup, no card

This page presents computed figures and filed financial data for information only. It is not investment advice, not a recommendation to buy or sell any security, and not a statement about what these shares will do. Sperio is a research tool, not an investment adviser. Figures are derived automatically from public filings and market data and may be incomplete, out of date or wrong. See the Terms & Disclaimer.